Famciclovir

• Herpes Zoster (Shingles)
• Genital Herpes
• Cold Sores (Herpes Labialis)
• Herpes Simplex Virus Infections

Famciclovir is an antiviral medication that is converted to penciclovir in the body, used for the treatment of herpes zoster (shingles), genital herpes, and recurrent herpes labialis (cold sores). This oral prodrug offers convenient dosing for both acute episodes and suppressive therapy.

Mechanism of Action

Famciclovir is a prodrug with no intrinsic antiviral activity. After oral administration, it is rapidly absorbed and converted to penciclovir by deacetylation and oxidation. Penciclovir is then selectively phosphorylated by viral thymidine kinase in infected cells to penciclovir monophosphate, which is further converted by cellular kinases to the active triphosphate form. Penciclovir triphosphate competitively inhibits viral DNA polymerase and is incorporated into the growing viral DNA chain, causing chain termination. The selectivity for infected cells (which contain viral thymidine kinase) minimizes toxicity to uninfected cells. Penciclovir triphosphate has a long intracellular half-life (7-20 hours), allowing for less frequent dosing.

Available Formulations

Famciclovir is available as film-coated tablets in 125 mg, 250 mg, and 500 mg strengths. The tablets can be taken with or without food. Generic formulations are available.

Medical Uses

Famciclovir is FDA-approved for acute treatment of herpes zoster (shingles) in immunocompetent adults, treatment and suppression of recurrent genital herpes in immunocompetent adults, treatment of recurrent herpes labialis (cold sores) in immunocompetent adults, and treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients. Early initiation of therapy (within 72 hours for shingles, at first sign of prodrome for recurrent herpes) maximizes effectiveness.

Dosing Guidelines

For herpes zoster, the dose is 500 mg every 8 hours for 7 days, starting within 72 hours of rash onset. For first episode genital herpes, 250 mg three times daily for 7-10 days is recommended. For recurrent genital herpes, 125 mg twice daily for 5 days or 1000 mg twice daily for 1 day. For suppression of genital herpes, 250 mg twice daily. For herpes labialis, a single dose of 1500 mg at the first sign of outbreak. Significant dose adjustments are required for renal impairment.

Important Safety Information

Famciclovir is generally well-tolerated. The most common adverse effects are headache, nausea, and diarrhea. Patients with compromised immune systems may have reduced responses. Acute renal failure has been reported in patients with underlying renal disease receiving inappropriately high doses. Dose adjustment is essential in renal impairment. Testicular toxicity was observed in animal studies at high doses; relevance to humans at therapeutic doses is unknown.

Drug Interactions

Probenecid and other drugs that compete for renal tubular secretion may increase penciclovir concentrations. Concurrent use with varicella or zoster vaccines may reduce vaccine efficacy; avoid administration within 24 hours before to 14 days after vaccination. Famciclovir is not significantly metabolized by or does not inhibit CYP450 enzymes, so drug interactions through this mechanism are minimal. No significant interaction with digoxin, cimetidine, or antacids has been observed.

Why Timing Matters More Than Which Antiviral Is Chosen

For shingles (herpes zoster), the benefit of an oral antiviral depends almost entirely on how quickly it is started. Treatment begun while new blisters are still appearing shortens the time to crusting and reduces the severity and duration of the acute pain. Treatment begun a week later, when the rash has already crusted over, does very little. This is why a suspected shingles rash is handled as a same-day problem rather than something to watch over a weekend, and why older adults, immunocompromised patients, and anyone with a rash near the eye or the tip of the nose are started on therapy even when the presentation is not textbook. An antiviral reliably shortens the acute illness. Its effect on post-herpetic neuralgia (PHN), the burning pain that can persist for months after the skin has healed, is more modest, and pain that outlasts the rash is treated in its own right rather than by extending the antiviral course.

The same logic governs recurrent genital herpes and cold sores, where the useful moment is the prodrome, the tingling, itching, or burning that precedes a visible lesion by hours. Patients given episodic therapy should keep the medication with them so it can be started at that point rather than after a pharmacy visit the following day. Patients whose recurrences are frequent, who have a partner who is not infected, or who find the unpredictability harder to live with than a daily tablet are usually better served by suppressive dosing, which also reduces transmission risk.

Famciclovir Compared With the Other Oral Antivirals

All three oral agents used for herpes infections are converted to a nucleoside analog that blocks viral DNA synthesis, and in comparative studies they perform similarly. The practical differences are dosing frequency and cost. Acyclovir is the least expensive but has poor oral bioavailability and must be taken up to five times a day for zoster, which patients in pain often fail to sustain. Valacyclovir is an acyclovir prodrug given three times daily for zoster and is the most commonly prescribed of the three. Famciclovir's distinguishing feature is the long intracellular persistence of its active metabolite, which is what allows the very short regimens used for cold sores and recurrent genital herpes. Any of the three can be substituted for another when cost, formulary coverage, or tolerability requires it, and none is clearly better than the others at preventing chronic pain.

All three depend on the kidney for elimination, so dose reduction in renal impairment is not optional. The most common serious problem with this class in older adults is not the infection but confusion, agitation, or hallucination caused by a dose that was never adjusted for kidney function, and it resolves when the dose is corrected. The other point worth making at the visit is prevention: the recombinant zoster vaccine prevents far more disease than any antiviral treats, and a shingles episode does not remove the need for it. The MedlinePlus famciclovir monograph sets out the patient instructions, and the National Institute on Aging overview of shingles describes the course of the illness and the role of vaccination. Our article on what every adult should know about shingles covers who should be vaccinated and when.

Special Populations

There are limited data on famciclovir use during pregnancy; animal studies showed no teratogenicity. Use during pregnancy only if clearly needed. A pregnancy registry existed but is now closed. It is unknown whether penciclovir is excreted in human breast milk; caution should be exercised. Safety and efficacy have not been established in pediatric patients. Elderly patients may require dose adjustment based on renal function. Significant dose reduction is required for patients with renal impairment (CrCl less than 60 mL/min). Patients with hepatic impairment showed lower penciclovir conversion; mild to moderate impairment requires no adjustment, but limited data exist for severe impairment.